Login / Signup

The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.

Shintaro YanazumeTakashi UshiwakaMika FukudaShinichi TogamiMasaki KamioHiroaki Kobayashi
Published in: Japanese journal of clinical oncology (2021)
The continuous use of bevacizumab beyond progressive disease improves post-progression survival suggesting its important role in first-line and recurrence treatment for ovarian cancer.
Keyphrases
  • free survival
  • metastatic colorectal cancer
  • multiple sclerosis